Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia

Stroke Clinical Trial

Official title:

Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02522351
• Other study ID #: 13.21. NRC
• Status: Completed
• Phase: N/A
• First received: July 13, 2015
• Last updated: October 4, 2017
• Start date: June 2015
• Est. completion date: September 2017

Study information

• Verified date: October 2017
• Source: Nestlé
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.

Description:

This trial will be a double blind, randomized, crossover, controlled, and interventional trial. Each subject will test 6 study samples in a randomized order at 5 mL of volume first then at 10 mL (12 samples maximum). The trial will last a maximum of one hour (a single study visit).

The total sample size is 47 enrolled subjects, 33 subjects completed. Patients will be females and males aged between 18 and 85 years with mild proven dysphagia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Mild dysphagia as defined by a score between 3 and 5 on the Dysphagia Outcome and Severity Scale

2. Patients aged between 18 and 85 years

3. Ischemic/hemorrhagic cerebral cause (stroke)

4. Able to understand French (oral and written)

5. Cognitive capacity enough to understand study procedures

6. Having health insurance (which in France is " social security")

7. Having signed the consent form.

Exclusion Criteria:

1. Any swallowing trouble not resulting from the current stroke

2. History of inhalation pneumopathy, i.e. any pulmonary inflammation linked to the path of a solid or liquid food in the respiratory system

3. Any physician diagnosed psychiatric illness

4. Patient with a digestive fistula

5. Any physician diagnosed food allergy

6. Any known allergy to barium or any compound of the contrast product

7. Confirmed or suspected perforated and occlusive syndrome

8. Pregnant or lactating women

9. Major respiratory disease needing oxygen (chronic respiratory insufficiency)

10. Subject who cannot be expected to comply with the study procedures, including consuming the test products.

11. Currently participating or having participated in another clinical trial during the month preceding the study

Related Conditions & MeSH terms

• Deglutition Disorders
• Dysphagia
• Stroke

Intervention

Other:
• Cereal extract concentration 1
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
• Cereal extract concentration 2
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
• Cereal extract concentration 3
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
• Thicken up clear concentration 1
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
• Thicken up clear concentration 2
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
• Thicken up clear concentration 3
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem

Locations

Country	Name	City	State
Belgium	Grand hopital de Charleroi	Charleroi
France	Centre Hospitalier Charles Nicolle	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
Nestlé

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of any systematic effect of cohesiveness on the efficacy of swallowing in dysphagic patients according to Rosenbek's Penetration-Aspiration Score (PAS) using videofluoroscopy	The PAS score across each bolus (5 mL and 10 mL)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing safety- prevalence of penetration	The prevalence of penetration in the population according to Rosenbek's PAS (score of 2-5) assessed using videofluoroscopy	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing safety- prevalence of aspiration	The prevalence of aspiration in the population according to Rosenbek's PAS (score of 6-8) assessed using videofluoroscopy	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Amount/volume of oral and pharyngeal residues	The amount/volume of oral and pharyngeal residues assessed using videofluoroscopy	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Prevalence of subjects with oral and pharyngeal residues	The prevalence of subjects of oral and pharyngeal residues assessed using videofluoroscopy	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Oral transit time (OTT, time between tongue tip elevation and arrival of the bolus at the ramus of the mandible)	Oral transit time (OTT, time between tongue tip elevation and arrival of the bolus at the ramus of the mandible)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Swallow response time (SRT, time between arrival of the bolus at the ramus of the mandible and pharyngeal phases of swallowing)	Swallow response time (SRT, time between arrival of the bolus at the ramus of the mandible and pharyngeal phases of swallowing)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Pharyngeal transit time (PTT, time between arrival of the bolus at the ramus of the mandible and the tail of the bolus passing through the upper esophageal sphincter)	Pharyngeal transit time (PTT, time between arrival of the bolus at the ramus of the mandible and the tail of the bolus passing through the upper esophageal sphincter)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Time to upper esophageal sphincter opening (UESO, time between tongue tip elevation and opening of the upper esophageal sphincter)	Time to upper esophageal sphincter opening (UESO, time between tongue tip elevation and opening of the upper esophageal sphincter)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function-Time to laryngeal vestibule opening (LVO, time between tongue tip elevation and pharyngeal phases of swallowing)	Time to laryngeal vestibule opening (LVO, time between tongue tip elevation and pharyngeal phases of swallowing)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Swallowing function- Time to laryngeal vestibule closure (LVC, time between tongue tip elevation and maximal laryngeal closure)	Time to laryngeal vestibule closure (LVC, time between tongue tip elevation and maximal laryngeal closure)	During the ingestion (videofluoroscopy), maximum during one hour.
Secondary	Subjective perception of ease of swallowing and oropharyngeal sensation.	This will be assessed from a questionnaire.	Right after ingredient ingestion, maximum during one hour.